Regulatory T Cells: Potential Target in Anticancer Immunotherapy

Taiwanese Journal of Obstetrics & Gynecology

卷:46

T-C Wu¹  Chien-Fu Hung¹  Nae-Fong Twu²  Ming-Huei Cheng²  Huann-Cheng Horng²  Ming-Shien Yen²  Chi-Mou Juang²  Kuo-Chang Wen²  Chiou-Chung Yuan²  Jiun-Yih Yeh²  Kuan-Chong Chao² 

[1] Department of Pathology, Obstetrics and Gynecology, Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA;

[2] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan;

关键词: CD25;    Foxp3;    immunotherapy;    regulatory T cells;   

DOI  :  10.1016/S1028-4559(08)60023-6

来源: DOAJ

【 摘 要 】

The concept of regulatory T cells was first described in the early 1970s, and regulatory T cells were called suppressive T cells at that time. Studies that followed have demonstrated that these suppressive T cells negatively regulated tumor immunity and contributed to tumor growth in mice. Despite the importance of these studies, there was extensive skepticism about the existence of these cells, and the concept of suppressive T cells left the center stage of immunologic research for decades. Interleukin-2 receptor α-chain, CD25, was first demonstrated in 1995 to serve as a phenotypic marker for CD4+ regulatory cells. Henceforth, research of regulatory T cells boomed. Regulatory T cells are involved in the pathogenesis of cancer, autoimmune disease, transplantation immunology, and immune tolerance in pregnancy. Recent evidence has demonstrated that regulatory T cellmediated immunosuppression is one of the crucial tumor immune evasion mechanisms and the main obstacle of successful cancer immunotherapy. The mechanism and the potential clinical application of regulatory T cells in cancer immunotherapy are discussed.

【 授权许可】

Unknown